Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicure Inc V.MPH

Alternate Symbol(s):  MCUJF

Healthcare Biotechnology
Medicure Inc. is a Canada-based pharmaceutical company. The Company is focused on the development and commercialization of therapies for the United States cardiovascular market. The focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company’s United... see more

Recent & Breaking News (TSXV:MPH)

Medicure To Announce Fiscal Year End 2019 Financial Results on April 15, 2020

PR Newswire April 13, 2020

Early Warning News Release - Dr. Albert D. Friesen Holdings in Medicure Inc.

Canada NewsWire December 31, 2019

Medicure Announces Preliminary Results of Substantial Issuer Bid

Canada NewsWire December 20, 2019

Medicure Announces the Completion of Shortened AGGRASTAT® Versus Integrilin® in Percutaneous Coronary Intervention (SAVI-PCI) Study

Canada NewsWire December 17, 2019

Medicure Announces Completion of Enrollment for FABOLUS-FASTER, Phase 4 Clinical Trial of Aggrastat (Tirofiban Hydrochloride) Injection VS Kengreal (Cangrelor) in Patients Undergoing Percutaneous Coronary Intervention (PCI)

Canada NewsWire December 12, 2019

Medicure Announces Settlement of Holdback Dispute from Apicore Sale

Canada NewsWire December 5, 2019

Medicure Files Patent Infringement Action

Canada NewsWire December 5, 2019

Medicure Reports Financial Results for Quarter Ended September 30, 2019

Canada NewsWire November 26, 2019

Medicure Q3 2019 Results and Conference Call Dates

Canada NewsWire November 19, 2019

Medicure Announces Commencement of Substantial Issuer Bid

Canada NewsWire November 13, 2019

Medicure Announces Intention to Commence Substantial Issuer Bid

PR Newswire November 4, 2019

Medicure Announces SMILE(TM)-HF Study Demonstrates Use of ReDS(TM) Results in 58% Reduction in Hospital Readmission Rate

Canada NewsWire October 15, 2019

Medicure Announces Preferred Pricing Agreement for Zypitamag(TM) with the AIDS Drug Assistance Program ("ADAP") Crisis Task Force

Canada NewsWire October 3, 2019

Medicure Announces Acquisition Of Full United States Ownership Of Zypitamag(TM)

Canada NewsWire September 30, 2019

Medicure Announces Launch of New and Improved ReDS(TM) PRO

Canada NewsWire September 17, 2019

Medicure Announces Settlement of Patent Infringement Action

Canada NewsWire August 21, 2019

Medicure Reports Financial Results for Quarter Ended June 30, 2019

Canada NewsWire August 8, 2019

Medicure Q2 2019 Results and Conference Call Dates

Canada NewsWire August 2, 2019

Medicure Announces Results of 2019 Annual Meeting of Shareholders

Canada NewsWire June 26, 2019

Medicure Announces Appoinment of Dr. Neil Owens as President and Chief Operating Officer

Canada NewsWire June 10, 2019